Wells Fargo
ELDN icon

Wells Fargo’s Eledon Pharmaceuticals ELDN Stock Holding History

Wells Fargo’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113K Sell
36,569
-32,337
-47% -$76.2K ﹤0.01% 5045
2025
Q4 		$104K Buy
68,906
+20,354
+42% +$48.4K ﹤0.01% 5376
2025
Q3 		$126K Buy
48,552
+11,396
+31% +$33.3K ﹤0.01% 5194
2025
Q2 		$101K Buy
+37,156
New +$111K ﹤0.01% 5191
2024
Q2 		– Sell
-189
Closed -$389 – 7050
2024
Q1 		$389 Buy
189
+3
+2% +$5 ﹤0.01% 6336
2023
Q4 		$335 Buy
186
+14
+8% +$19 ﹤0.01% 6474
2023
Q3 		$236 Buy
172
+26
+18% +$35 ﹤0.01% 6544
2023
Q2 		$200 Buy
146
+60
+70% +$125 ﹤0.01% 6704
2023
Q1 		$203 Buy
86
+2
+2% +$5 ﹤0.01% 6771
2022
Q4 		$192 Buy
84
+2
+2% +$5 ﹤0.01% 6630
2022
Q3 		$0 Sell
82
-10
-11% -$32 ﹤0.01% 6809
2022
Q2 		$0 Buy
92
+4
+5% +$12 ﹤0.01% 6957
2022
Q1 		$0 Hold
88
– – ﹤0.01% 7223
2021
Q4 		$0 Hold
88
– – ﹤0.01% 7342
2021
Q3 		$1K Sell
88
-4
-4% -$28 ﹤0.01% 6691
2021
Q2 		$1K Sell
92
-1
-1% -$9 ﹤0.01% 6649
2021
Q1 		$1K Buy
93
+85
+1,063% +$1.28K ﹤0.01% 6709
2020
Q4 		$0 Buy
8
+3
+60% +$57 ﹤0.01% 6588
2020
Q3 		$0 Buy
5
+1
+25% +$10 ﹤0.01% 6438
2020
Q2 		$0 Hold
4
– – ﹤0.01% 6390
2020
Q1 		$0 Buy
+4
New +$38 ﹤0.01% 6325
2016
Q3 		– Hold
0
– – – 6206
2016
Q2 		– Sell
-2
Closed -$2.21K – 6147
2016
Q1 		$1K Buy
+2
New +$1.96K ﹤0.01% 6092
2015
Q4 		– Hold
0
– – – 6263
2015
Q3 		– Sell
-3
Closed -$6.18K – 6055
2015
Q2 		$6K Sell
3
-3
-50% -$5.8K ﹤0.01% 5953
2015
Q1 		$11K Buy
+6
New +$13.2K ﹤0.01% 5591

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Wells Fargo's ELDN Position: Q1 2026 in Review

Wells Fargo reduced its Eledon Pharmaceuticals (ELDN) stake by 47% in Q1 2026, selling an estimated $76.2K and leaving 36,569 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #5045.

Wells Fargo first reported a position in ELDN in Q1 2015 and has held it in 24 quarters since. The position peaked at $126K in Q3 2025. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Wells Fargo held 36,569 shares of Eledon Pharmaceuticals worth $113K as of Q1 2026.
  • Wells Fargo sold 32,337 Eledon Pharmaceuticals shares in Q1 2026, an estimated $76.2K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5045 holding.
  • Wells Fargo first reported a position in Eledon Pharmaceuticals in Q1 2015 and has held it in 24 quarters since.
  • Wells Fargo's Eledon Pharmaceuticals position peaked at $126K in Q3 2025.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.